Search

Board

The EHA Board is the governing body of the association and deals with issues of policy. The Board sets the goals and objectives of the association in conformity with the EHA's statutes.

Read more

Genome sequencing of thousands of patients with rare blood disorders

Approximately 3M people have a rare bleeding disorder or disease of platelets, which are the cell fragments that help blood clot. The genetic causes of dozens of such disorders are known (e. g.

Read more

Stopping tyrosine kinase inhibitors in a very large cohort of European chronic myeloid leukemia patients: results of the EURO-SKI trial

Tyrosine kinase inhibitors (TKI) have substantially improved survival in patients with chronic myeloid leukemia in chronic phase. However, treatment is in clinical practice considered life-long.

Read more

Does the patient with myelofibrosis feel better through Pacritinib?

Pacritinib is an oral next-generation multikinase inhibitor with specificity for JAK2 and FLT3 being evaluated to treat myelofibrosis in two Phase 3 trials.

Read more

Blood Disorders: European Hematologists gather in Stockholm, June 13-16, 2013

About the EHA Annual Congress

Hematology is a specialty that covers everything to do with blood: its origin in the bone marrow, diseases of blood and their treatments.

Read more

Press Release: Better funding for research into blood diseases will save more lives

“Haematology is probably the area of medicine that has progressed the most in recent years”, said Professor Robin Foà of “La Sapienza” University of Rome.

Read more

Healthcare-affiliated professional membership

You don't need to be scientific researcher or a physician to join our vibrant community.

Read more